CAPREOMYCIN

Antibacterial activity

Used in combination with other antituberculosis medications in the treatment of pulmonary tuberculosis caused by Mycobacterium tuberculosis after failure with the primary medications (isoniazid, aminosalicylic acid, streptomycin, ethambutol, and rifampin) or when these cannot be used because of toxicity or development of resistant tubercle bacilli
Active against human strains of Mycobacterium tuberculosis

Pregnancy Risk Factor

Class C

Contraindication/Precaution

Hypersensitivity to capreomycin or any component
Use caution if nursing
Use caution if earring dysfunction/8 cranial nerve damage
Use caution in the presence of myasthenia gravis/parkinsonism
Use with non-antituberculous drugs having ototoxic potential should be undertaken only with great caution.
Use caution if impaired renal function or if other nephrotoxic agent are used
Safety of the use of capreomycin sulfate in infants and children has not been established.

Mechanism of Action

N/A

Pharmacodynamics

Metabolism: N/A
Half-life: 3-6 hours, changes with renal function
Elimination: excreted in urine and some in bile

Dosage

Children:

Safety of the use of capreomycin sulfate in infants and children has not been established.

Adults: (max 20mg/kg/day)

1 g IM qd for 60-120 days, followed by 1 g IM 2-3 times/week
always administered in combination with at least 1 other antituberculosis agent

Dose VS renal function

Cr. clearance (ml/min):
<10: 2.4 mg/kg IM q24h 10-20: 2.4-3.6 mg/kg IM q24h 20-30: 3.6-4.7 mg/kg IM q24h 30-40: 4.7-5.9 mg/kg IM q24h 40-50: 5.9-7 mg/kg IM q24h 50-60: 7-8.2 mg/kg IM q24h 60-80: 8.2-10.4 mg/kg IM q24h 80-100: 10.4-12.7 mg/kg IM q24h 100-110: 12.7-13.9 mg/kg IM q24h >110: unchanged

Dialysis
Hemo: N/A
CAPD:  N/A